Abstract
Bayesian analysis using a virus dynamics model is demonstrated to facilitate hypothesis testing of patterns in clinical time-series. Our Markov chain Monte Carlo implementation demonstrates that the viraemia time-series observed in two sets of hepatitis B patients on antiviral (lamivudine) therapy, chronic carriers and liver transplant patients, are significantly different, overcoming clinical trial design differences that question the validity of non-parametric tests. We show that lamivudine-resistant mutants grow faster in transplant patients than in chronic carriers, which probably explains the differences in emergence times and failure rates between these two sets of patients. Incorporation of dynamic models into Bayesian parameter analysis is of general applicability in medical statistics.
Full Text
The Full Text of this article is available as a PDF (214.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cane P. A., Mutimer D., Ratcliffe D., Cook P., Beards G., Elias E., Pillay D. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther. 1999;4(1):7–14. [PubMed] [Google Scholar]
- Chayama K., Suzuki Y., Kobayashi M., Kobayashi M., Tsubota A., Hashimoto M., Miyano Y., Koike H., Kobayashi M., Koida I. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology. 1998 Jun;27(6):1711–1716. doi: 10.1002/hep.510270634. [DOI] [PubMed] [Google Scholar]
- Davies S. E., Portmann B. C., O'Grady J. G., Aldis P. M., Chaggar K., Alexander G. J., Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991 Jan;13(1):150–157. [PubMed] [Google Scholar]
- Lai C. L., Chien R. N., Leung N. W., Chang T. T., Guan R., Tai D. I., Ng K. Y., Wu P. C., Dent J. C., Barber J. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998 Jul 9;339(2):61–68. doi: 10.1056/NEJM199807093390201. [DOI] [PubMed] [Google Scholar]
- McMillan J. S., Shaw T., Angus P. W., Locarnini S. A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995 Jul;22(1):36–43. [PubMed] [Google Scholar]
- Mutimer D., Pillay D., Dragon E., Tang H., Ahmed M., O'Donnell K., Shaw J., Burroughs N., Rand D., Cane P. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol. 1999 Apr;30(4):715–721. doi: 10.1016/s0168-8278(99)80204-9. [DOI] [PubMed] [Google Scholar]
- Nowak M. A., Bonhoeffer S., Hill A. M., Boehme R., Thomas H. C., McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398–4402. doi: 10.1073/pnas.93.9.4398. [DOI] [PMC free article] [PubMed] [Google Scholar]